Eli Lilly general manager Tori Brown said, “The report highlights a once in a generation opportunity to act on Alzheimer’s disease. It is good for patients, good for families and carers, good for health and aged care systems, and good for the economy." …
New report unveils hidden cost of Alzheimer’s disease, with cases to double by 2050
October 10, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 - - Latest News -
Cynata completes patient enrolment in Phase 2 trial for aGvHD therapy
December 15, 2025 - - Australian Biotech -
Prescient secures European approval to launch PTX-100 trial for rare lymphoma
December 15, 2025 - - Australian Biotech -
Orthocell lodges European and UK regulatory application for Remplir
December 15, 2025 - - Australian Biotech -
Neuren wins second FDA approval for trofinetide with launch of formulation
December 15, 2025 - - Australian Biotech -
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 - - Australian Biotech -
Radiopharm Theranostics reports high success rate in Phase 2b imaging trial
December 15, 2025 - - Australian Biotech